ISSN 0303-5212
 
2026, Vol: 51, Issue: 2
51 / 2Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Author_Certificate-old
Bank Reciept

Short Communication 
RMJ. 2016; 41(4): 519-521


Experience of GLP-1 agonist Exenatide in the management of type 2 diabetic obese Pakistani patients

Osama Ishtiaq, Rida Kamal, Tahir Iqbal, Batool Zehra.


Abstract
Objective: We evaluated the use of Exenatide in terms of weight reduction and improvement of glycemic control, in patients with type 2 diabetes and obesity from Pakistan. Methodology: The study was done in Shifa International Hospital, Islamabad from year 2013 to 2014. Exenatide was prescribed to 45 patients, in which 19 patients had completed follow-ups. HbA1c, BMI and weight were recorded before and after the treatment. Side effects and reason for early discontinuation were also noted. Results: The concurrent use of Exenatide along with other anti-diabetic medications, enabled patients to reduce an average weight of 6.6kg (average decrease in BMI was 1.82kg/m2) and HbA1c levels of 0.6% over a period of 5 months, making it a promising therapeutic agent in obese and diabetic patients. The most common side effect noted was nausea. Conclusion: Exenatide has a potential to achieve reasonable weight loss and mild improvements in glycemic control in Pakistani obese and diabetic patients.

Key words: Exenatide, diabetes mellitus, obesity, GLP-1 agonist


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Osama Ishtiaq
Articles by Rida Kamal
Articles by Tahir Iqbal
Articles by Batool Zehra
on Google
on Google Scholar

How to Cite this Article
Pubmed Style

Ishtiaq O, Kamal R, Iqbal T, Zehra B. Experience of GLP-1 agonist Exenatide in the management of type 2 diabetic obese Pakistani patients. RMJ. 2016; 41(4): 519-521.

Web Style

Ishtiaq O, Kamal R, Iqbal T, Zehra B. Experience of GLP-1 agonist Exenatide in the management of type 2 diabetic obese Pakistani patients. https://www.rmj.org.pk/?mno=242275 [Access: June 27, 2026].

AMA (American Medical Association) Style

Ishtiaq O, Kamal R, Iqbal T, Zehra B. Experience of GLP-1 agonist Exenatide in the management of type 2 diabetic obese Pakistani patients. RMJ. 2016; 41(4): 519-521.


Vancouver/ICMJE Style

Ishtiaq O, Kamal R, Iqbal T, Zehra B. Experience of GLP-1 agonist Exenatide in the management of type 2 diabetic obese Pakistani patients. RMJ. (2016), [cited June 27, 2026]; 41(4): 519-521.


Harvard Style

Ishtiaq, O., Kamal, . R., Iqbal, . T. & Zehra, . B. (2016) Experience of GLP-1 agonist Exenatide in the management of type 2 diabetic obese Pakistani patients. RMJ, 41 (4), 519-521.


Turabian Style

Ishtiaq, Osama, Rida Kamal, Tahir Iqbal, and Batool Zehra. 2016. Experience of GLP-1 agonist Exenatide in the management of type 2 diabetic obese Pakistani patients. Rawal Medical Journal, 41 (4), 519-521.


Chicago Style

Ishtiaq, Osama, Rida Kamal, Tahir Iqbal, and Batool Zehra. "Experience of GLP-1 agonist Exenatide in the management of type 2 diabetic obese Pakistani patients." Rawal Medical Journal 41 (2016), 519-521.


MLA (The Modern Language Association) Style

Ishtiaq, Osama, Rida Kamal, Tahir Iqbal, and Batool Zehra. "Experience of GLP-1 agonist Exenatide in the management of type 2 diabetic obese Pakistani patients." Rawal Medical Journal 41.4 (2016), 519-521. Print.


APA (American Psychological Association) Style

Ishtiaq, O., Kamal, . R., Iqbal, . T. & Zehra, . B. (2016) Experience of GLP-1 agonist Exenatide in the management of type 2 diabetic obese Pakistani patients. Rawal Medical Journal, 41 (4), 519-521.


Author LoginReviewer LoginEditorial PoliciesConflict of Interest PolicyPlagiarism PolicyAdvertising Policy

About Rawal Medical Journal

Publication, subscription and Editorial office PMA House G/220-B Liaquat Road, Rawalpindi. Phone: 051-555-9812, Fax: 051-553-7088 Email: drnkhokhar@ya ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information